PrecivityAD2™ – Alzheimer’s Disease Blood Test

PrecivityAD2™ is an advanced blood test designed to help evaluate biological markers associated with Alzheimer’s disease. The test measures key proteins in the blood that are linked to amyloid plaque formation in the brain—one of the primary pathological features of Alzheimer’s disease.

Using a small blood sample, the test analyzes biomarkers including amyloid beta proteins and phosphorylated tau (pTau217) to generate an Amyloid Probability Score, which helps indicate the likelihood that amyloid plaques are present in the brain. This information can support physicians in evaluating patients with symptoms such as mild cognitive impairment (MCI), memory loss, or early signs of dementia.

What the Test Covers

PrecivityAD2 evaluates important biomarkers associated with Alzheimer’s pathology, including:

• Amyloid beta protein ratios associated with plaque formation
• Phosphorylated tau (pTau217) – a key marker linked to Alzheimer’s disease
• Amyloid Probability Score (APS) indicating likelihood of amyloid plaques

Why Consider PrecivityAD2

• Blood-based test associated with Alzheimer’s disease pathology
• Helps assess likelihood of amyloid plaque presence in the brain
• Supports evaluation of memory loss or cognitive decline
• Provides information to help guide clinical evaluation and management

PrecivityAD2 is intended for individuals age 50 and older experiencing cognitive symptoms and can provide valuable information to support physicians in the assessment of Alzheimer’s disease.